@Article{096504016X14562725373879,
AUTHOR = {Zhiying Shao, Shalini Chaudhri, Meng Guo, Longzhen Zhang, Daniel Rea},
TITLE = {Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study},
JOURNAL = {Oncology Research},
VOLUME = {23},
YEAR = {2015},
NUMBER = {6},
PAGES = {291--302},
URL = {http://www.techscience.com/or/v23n6/57541},
ISSN = {1555-3906},
ABSTRACT = {Triple negative breast cancer (TNBC) is a phenotype of breast cancer with aggressive clinical behavior. Because 
of the absence of optimal treatment, the prognosis of this disease is poor. The main purpose of this study was to 
detect the response to neoadjuvant chemotherapy (NACT) in a TNBC cohort and compare the long-term survival between patients with and without pathological complete response (pCR). A total of 53 patients diagnosed 
with TNBC from 2005 to 2013 who received NACT at the University Hospital Birmingham were enrolled in 
this study. Overall survival (OS) and progression-free survival (PFS) were compared between the pCR group 
and non-pCR group. Demographic information and clinical or pathologic parameters were also analyzed to 
explore potential predictive and prognostic factors. Fourteen patients (26.4%) achieved pCR to NACT. In 
univariate analysis, patients with pCR had longer PFS time (p=0.013) and OS time (p=0.054) compared with 
their counterparts without pCR. In multivariate analysis, the existence of lymphovascular invasion (LVI) significantly reduced OS (HR=17.404, 95% CI=2.923–103.644) and PFS (HR=7.776, 95% CI=1.645–36.753). 
The achievement of pCR to NACT can significantly postpone the incidence of disease progression in patients 
with TNBC. There is not enough evidence showing its influence on ultimate survival. LVI may be a more 
potent prognostic factor than pCR in the TNBC cohort.},
DOI = {10.3727/096504016X14562725373879}
}